Galectin Therapeutics Q1 2024 GAAP EPS $(0.19) Misses $(0.16) Estimate
Portfolio Pulse from Benzinga Newsdesk
Galectin Therapeutics reported a Q1 2024 GAAP EPS of $(0.19), missing the estimate of $(0.16).
May 15, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Galectin Therapeutics reported a Q1 2024 GAAP EPS of $(0.19), which is worse than the estimated $(0.16). This miss could negatively impact investor sentiment and the stock price in the short term.
The reported EPS of $(0.19) is below the expected $(0.16), indicating worse-than-expected financial performance. This miss is likely to lead to a negative reaction from investors, potentially driving the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100